Background
People with HIV (PWH) face an elevated risk of cardiovascular diseases, including heart failure (HF), due to a combination of traditional risk factors and HIV-related mechanisms such as chronic inflammation and immune dysregulation. Despite advances in antiretroviral therapy (ART), the incidence and predictors of HF in PWH remain inadequately characterized. The REPRIEVE trial aimed to quantify HF risk in a global cohort of PWH with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk.
